Letter to the Editor in Response to "Immunogenicity of Tumor Necrosis Factor Antagonists and Effect of Dose Escalation on Anti-Drug Antibodies and Serum Drug Concentrations in Inflammatory Bowel Disease".
Inflamm Bowel Dis
; 28(5): e59-e60, 2022 05 04.
Article
in En
| MEDLINE
| ID: mdl-35512142
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Inflammatory Bowel Diseases
/
Tumor Necrosis Factor Inhibitors
Limits:
Humans
Language:
En
Journal:
Inflamm Bowel Dis
Journal subject:
GASTROENTEROLOGIA
Year:
2022
Document type:
Article
Affiliation country:
Ireland
Country of publication:
United kingdom